1.Valerio M,
Willis S,
van der Meulen J,
Emberton M,
Ahmed HU.
Methodological considerations in assessing the utility of imaging in
early prostate cancer.
Curr Opin Urol 2015; 25: 536–42.
2.Perera M,
Papa N,
Christidis D,
Wetherell D,
Hofman MS,
Murphy DG,
et al.
Sensitivity,
specificity,
and predictors of positive (68)Ga-prostate-specific
membrane antigen positron emission tomography in advanced prostate
Cancer: a systematic review and meta-analysis.
Eur Urol.
2016;70:926–37.
3.von Eyben FE,
Picchio M,
von Eyben R,
Rhee H,
Bauman G.
(68)Ga-labeled
prostate-specific membrane antigen ligand positron emission tomography/
computed tomography for prostate Cancer: a systematic review and
meta-analysis.
Eur Urol Focus.
2016
4.Afshar-Oromieh A,
Malcher A,
Eder M,
Eisenhut M,
Linhart HG,
Hadaschik BA,
et
al.
PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of
prostate cancer: biodistribution in humans and first evaluation of tumour
lesions.
Eur J Nucl Med Mol Imaging.
2013;40:486–95
5.Calais J,
Czernin J,
Cao M,
Kishan AU,
Hegde JV,
Shaverdian N,
et al.
68Ga-PSMA-11 PET/CT mapping of prostate Cancer biochemical recurrence after
radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL:
impact on salvage radiotherapy planning.
J Nucl Med.
2018;59:230–7.
6.Sheikhbahaei S,
Afshar-Oromieh A,
Eiber M,
Solnes LB,
Javadi MS,
Ross AE,
et al.
Pearls and pitfalls in clinical interpretation of prostate-specific
membrane antigen (PSMA)-targeted PET imaging.
Eur J Nucl Med Mol
Imaging.
2017
7.Ristau BT,
O’Keefe DS,
Bacich DJ.
The prostate-specific membrane antigen:
lessons and current clinical implications from 20 years of research.
Urol
Oncol.
2014;32:272–9.
8.Verburg FA,
Pfister D,
Heidenreich A,
Vogg A,
Drude NI,
Vöö S,
et al.
Extent of
disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC
PET/CT in relation to PSA levels,
PSA doubling time and Gleason score.
Eur J Nucl Med Mol Imaging.
2016;43:397–403
9.Shetty D,
Loh H,
Bui C,
et al.
Elevated 68Ga prostate-specific membrane antigen
activity in metastatic non-small cell lung cancer.
Clin Nucl Med.
2016;
41:414–416.
10.Pyka T,
Weirich G,
Einspieler I,
et al.
68Ga-PSMA-HBED-CC PET for differential
diagnosis of suggestive lung lesions in patients with prostate cancer.
J Nucl Med.
2016;57:367–371.
11.Haffner MC,
Kronberger IE,
Ross JS,
et al.
Prostate-specific membrane antigen
expression in the neovasculature of gastric and colorectal cancers.
Hum Pathol.
2009;40:1754–1761.
12.WernickeAG,
Varma S,
Greenwood EA,
et al.
Prostate-specificmembrane antigen
expression in tumor-associated vasculature of breast cancers.
APMIS.
2014;122:482–489.
13.Nomura N,
Pastorino S,
Jiang P,
et al.
Prostate specific membrane antigen
(PSMA) expression in primary gliomas and breast cancer brain metastases.
Cancer Cell Int.
2014;14:26.
14,Chang SS,
Reuter VE,
HestonWD,
et al.
Five different anti-prostate-specific
membrane antigen (PSMA) antibodies confirm PSMA expression in tumorassociated
neovasculature.
Cancer Res.
1999;59:3192–3198.
15,Verburg FA,
Krohn T,
Heinzel A,
et al.
First evidence of PSMA expression in
differentiated thyroid cancer using [68Ga]PSMA-HBED-CC PET/CT.
Eur J
Nucl Med Mol Imaging.
2015;42:1622–1623.
16.Kanthan GL,
Coyle L,
Kneebone A,
et al.
Follicular lymphoma showing avid uptake
on 68Ga PSMA-HBED-CC PET/CT.
Clin Nucl Med.
2016;41:500–501.
17.Law WP,
Fiumara F,
FongW,
et al.
Gallium-68 PSMA uptake in adrenal adenoma.
J Med Imaging Radiat Oncol.
2016;60:514–7
18.Kobe C,Maintz D,
Fischer T,
et al.
Prostate-specific membrane antigen PET/CT
in splenic sarcoidosis.
Clin Nucl Med.
2015;40:897–898.
19.WangW,
Tavora F,
Sharma R,
et al.
PSMAexpression in schwannoma: a potential
clinicalmimicker ofmetastatic prostate carcinoma.
Urol Oncol.
2009;27:525–528.
20.Artigas C,
Alexiou J,
Garcia C,
et al.
Paget bone disease demonstrated on
(68)Ga-PSMA ligand PET/CT.
Eur J Nucl Med Mol Imaging.
2016;43:
195–196.
21.Andreas G.
Wibmer,
MD Irene A.
Burger,
MD Evis Sala,
MD,
PhD Hedvig Hricak,
MD,
PhD Wolfgang A.
Weber,
MD Hebert Alberto Vargas,
MD
Molecular Imaging of Prostate Cancer1 RadioGraphics 2016; 36:0000–0000 )
22.LUKAS BUBENDORF,
MD,
ALAIN SCHOPFER,
MD,
URS WAGNER,
MD,
GUIDO SAUTER,
MD,
HOLGER MOCH,
MD,
NIELS WILLI,
MD,THOMAS C.
GASSER,
MD,
AND MICHAEL J.
MIHATSCH,
MD-Metastatic Patterns of Prostate Cancer: An Autopsy Study of 1,589 Patients-